Speransa Therapeutics

Executive Summary

Speransa Therapeutics is a commercial-stage medical device company dedicated to combating the opioid crisis through its flagship product, the S.T. Genesis. This FDA-cleared, non-invasive Percutaneous Nerve Field Stimulator (PNFS) targets specific brain areas to alleviate pain and anxiety, effectively managing opioid withdrawal symptoms during the critical initial phase. By offering a drug-free solution, Speransa addresses a pressing public health need, providing an alternative to medication-assisted treatments that can have their own abuse potential. The company is based in Cambridge, Massachusetts, and has been operational since 2018. The S.T. Genesis has the potential to transform withdrawal management, reducing the burden on healthcare systems and improving patient outcomes. Speransa's competitive advantage lies in its unique non-invasive approach, which is both safe and easy to administer. As the opioid epidemic continues, demand for effective withdrawal solutions is growing. Speransa is well-positioned to capture market share, with opportunities for expansion into other substance use disorders and pain management. With an FDA-cleared product and a focus on commercialization, the company represents a compelling investment opportunity in the addiction treatment space.

Upcoming Catalysts (preview)

• Q4 2026Commercial Milestone: Achievement of $10M in Annual Revenue60% success
• Q2 2027FDA 510(k) Clearance for Expanded Indication (e.g., Alcohol Withdrawal)40% success
• Q3 2026Strategic Partnership with Major Healthcare Network for Distribution50% success